On Monday, Zydus Healthcare which is a subsidiary of Cadila Healthcare has acquired two abbreviated new drug applications (ANDAs) from Teva Pharmaceutical in the US for an undisclosed amount.
Cadila Healthcare has said in a BSE filing that “Zydus has strengthened its US portfolio with the acquisition of two ANDAs from Teva that are being divested by Teva as a pre-condition to its acquisition of Allergan’s generic business.”
It has added that “The acquisition of these ANDAs is contingent on the closing of the Teva-Allergan Genercis transaction and approval by the US Federal Trade Commission.”
Moreover, the financial details of the transaction have not been disclosed by the company.
